Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EORTC ILOC study
2017-001375-22Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in colorectal cancer (CRC), sponsored by European Organisation for Research and Treatment of Cancer. Started Jan 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2017-001375-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001375-22.